LTRN
Lantern Pharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.64
−4.05%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +6.1%
- EBIT
- +24.6%
- EPS
- +9.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +74.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- +17.6%
- EBIT
- +19.1%
- Net income
- +17.6%
- EPS
- +99.9%
- Free cash flow
- +12.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026